Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Debt (2020 - 2025)

Eton Pharmaceuticals' Total Debt history spans 6 years, with the latest figure at $30.4 million for Q3 2025.

  • For Q3 2025, Total Debt rose 636.17% year-over-year to $30.4 million; the TTM value through Sep 2025 reached $30.4 million, up 636.17%, while the annual FY2024 figure was $29.8 million, 454.11% up from the prior year.
  • Total Debt for Q3 2025 was $30.4 million at Eton Pharmaceuticals, up from $30.2 million in the prior quarter.
  • Across five years, Total Debt topped out at $30.4 million in Q3 2025 and bottomed at $364000.0 in Q2 2022.
  • The 5-year median for Total Debt is $1.5 million (2023), against an average of $7.0 million.
  • The largest annual shift saw Total Debt tumbled 51.4% in 2022 before it surged 636.17% in 2025.
  • A 5-year view of Total Debt shows it stood at $1.4 million in 2021, then dropped by 27.15% to $1.0 million in 2022, then soared by 420.81% to $5.4 million in 2023, then soared by 454.11% to $29.8 million in 2024, then grew by 1.87% to $30.4 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Total Debt are $30.4 million (Q3 2025), $30.2 million (Q2 2025), and $29.8 million (Q4 2024).